These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 706183)

  • 21. Urinary osmolarity in late stage nephritis and nephrosis.
    Túri S; Ormos J; Sztriha L; Szepesi G
    Acta Paediatr Acad Sci Hung; 1979; 20(2-3):171-6. PubMed ID: 546014
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intranasal DDAVP test in children.
    Helin I
    J Urol; 1982 Jan; 127(1):78-9. PubMed ID: 7057511
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Detection of renal impairment in cases of chronic abuse of analgesics by administration of desamino-D-arginine vasopressin.
    Wambach G; Bönner G; Kleinpass H; Dopatka A; Kaufmann W
    Arzneimittelforschung; 1989 Mar; 39(3):387-90. PubMed ID: 2569306
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Comparative studies on the activation of the fibrinolytic system by venous stasis and the administration of DDAVP].
    Huyke R; Vogel G; Lauten G
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1984; 111(4):480-3. PubMed ID: 6083914
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of renal concentrating ability with DDAVP and pitressin.
    Herbai G; Ljunghall S
    Scand J Urol Nephrol; 1983; 17(1):69-71. PubMed ID: 6867627
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Urinary concentration capacity in neonatal hydronephrosis].
    Orejas Rodríguez-Arango G; García Vicente S; Rey Galán C; Ramos Aparicio A; Santos Rodríguez F; Málaga Guerrero S
    An Esp Pediatr; 1993 Jan; 38(1):10-2. PubMed ID: 8439070
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Central and nephrogenic diabetes insipidus. Use of the intravenous DDAVP test].
    Vanelli M; Bernasconi S; Giovannelli G
    Minerva Pediatr; 1977 Mar; 29(10):721-5. PubMed ID: 875941
    [No Abstract]   [Full Text] [Related]  

  • 28. [Treatment of diabetes insipidus with synthetic vasopressin derivatives (effect of 1-deamino-8-D-arginine vasopressin and 1-deamino-valine-8-D-arginine vasopressin)].
    Czakó L; László F; Manning M
    Orv Hetil; 1980 Mar; 121(13):773-8. PubMed ID: 7383655
    [No Abstract]   [Full Text] [Related]  

  • 29. Assessment of renal concentrating ability.
    Curtis JR; Donovan BA
    Br Med J; 1979 Feb; 1(6159):304-5. PubMed ID: 421089
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intranasal DDAVP-test in the study of renal concentrating capacity in children with recurrent urinary tract infections.
    Abyholm G; Monn E
    Eur J Pediatr; 1979 Mar; 130(3):149-54. PubMed ID: 421696
    [TBL] [Abstract][Full Text] [Related]  

  • 31. DDAVP test for assessment of renal concentrating capacity in infants and children.
    Monnens L; Smulders Y; van Lier H; de Boo T
    Nephron; 1981; 29(3-4):151-4. PubMed ID: 7329489
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of vasopressin analogues (DDAVP, DVDAVP) in the form of sublingual tablets in central diabetes insipidus.
    Laczi F; Mezei G; Julesz J; Lázló FA
    Int J Clin Pharmacol Ther Toxicol; 1981 Feb; 19(2):63-8. PubMed ID: 7216552
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 1-deamino-/4-valine-8-D-arginine/-vasopressin (dVDAVP), a new synthetic vasopressin analog for treating diabetes insipidus.
    László FA; Czakó L
    Int J Clin Pharmacol Ther Toxicol; 1982 Jan; 20(1):39-43. PubMed ID: 7056603
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dose-dependent stimulation of renal prostaglandin synthesis by deamino-8-D-arginine vasopressin in rats with hereditary diabetes insipidus.
    Walker LA; Frölich JC
    J Pharmacol Exp Ther; 1981 Apr; 217(1):87-91. PubMed ID: 7205662
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of lysine-vasopressin (LVP) and 1-deamino-8-D-arginine-vasopressin (dDAVP) upon electrical potential, short-circuit current and transepithelial D.C. resistance of the frog skin.
    Bakos P; Ponec J; Lichardus B
    Gen Physiol Biophys; 1984 Aug; 3(4):297-305. PubMed ID: 6094299
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of arginine-8-vasopressin and 1-deamino-8-D-arginine-vasopressin on ACTH secretion in rats.
    László FA; Janáky T; Julesz J; Kárteszi M; Makara GB; Stark E
    Endocrinol Exp; 1983 Jun; 17(2):133-6. PubMed ID: 6309504
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ten-year experience with DDAVP in treatment of diabetes insipidus.
    Marek J; Loutocký A; Pacovský V; Zaoral M
    Endokrinologie; 1978 May; 72(2):188-94. PubMed ID: 738214
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of alpha-thalassemia and sickle polymerization tendency on the urine-concentrating defect of individuals with sickle cell trait.
    Gupta AK; Kirchner KA; Nicholson R; Adams JG; Schechter AN; Noguchi CT; Steinberg MH
    J Clin Invest; 1991 Dec; 88(6):1963-8. PubMed ID: 1752955
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The influence of a single dose of vasopressin analogs on human renal potassium excretion.
    Nádvorníková H; Schück O
    Int J Clin Pharmacol Ther Toxicol; 1982 Apr; 20(4):155-8. PubMed ID: 7076344
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The antidiuretic action of 1-deamino-8-D-arginine vasopressin (DDAVP) in man.
    Radó JP; Marosi J; Szende L; Borbély L; Takó J; Fischer J
    Int J Clin Pharmacol Biopharm; 1976 Apr; 13(3):199-209. PubMed ID: 950263
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.